In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

(AP Photo/Amanda Andrade-Rhoades, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Makers of the ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.